Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4869723
Max Phase: Preclinical
Molecular Formula: C54H71F15N14O17
Molecular Weight: 903.10
Molecule Type: Unknown
Associated Items:
ID: ALA4869723
Max Phase: Preclinical
Molecular Formula: C54H71F15N14O17
Molecular Weight: 903.10
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(=O)N[C@@H](CCCN)C(=O)NC(=O)[C@H](C)NC(=O)[C@H](CCNC(=N)N)NCCN1CCN(CCC(=O)NC2CCN(CC(=O)N3c4ccccc4NC(=O)c4ccccc43)CC2)CC1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
Standard InChI: InChI=1S/C44H66N14O7.5C2HF3O2/c1-29(40(62)54-43(65)35(10-7-17-45)51-30(2)59)50-42(64)34(13-18-49-44(46)47)48-19-23-56-26-24-55(25-27-56)22-16-38(60)52-31-14-20-57(21-15-31)28-39(61)58-36-11-5-3-8-32(36)41(63)53-33-9-4-6-12-37(33)58;5*3-2(4,5)1(6)7/h3-6,8-9,11-12,29,31,34-35,48H,7,10,13-28,45H2,1-2H3,(H,50,64)(H,51,59)(H,52,60)(H,53,63)(H4,46,47,49)(H,54,62,65);5*(H,6,7)/t29-,34-,35-;;;;;/m0...../s1
Standard InChI Key: AFDRPMSXUAAFLL-XAJDFITESA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 903.10 | Molecular Weight (Monoisotopic): 902.5239 | AlogP: -1.27 | #Rotatable Bonds: 21 |
Polar Surface Area: 292.55 | Molecular Species: BASE | HBA: 13 | HBD: 10 |
#RO5 Violations: 3 | HBA (Lipinski): 21 | HBD (Lipinski): 12 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.38 | CX Basic pKa: 12.00 | CX LogP: -4.34 | CX LogD: -8.73 |
Aromatic Rings: 2 | Heavy Atoms: 65 | QED Weighted: 0.05 | Np Likeness Score: -0.55 |
1. Weinhart CG, Wifling D, Schmidt MF, Neu E, Höring C, Clark T, Gmeiner P, Keller M.. (2021) Dibenzodiazepinone-type muscarinic receptor antagonists conjugated to basic peptides: Impact of the linker moiety and unnatural amino acids on M2R selectivity., 213 [PMID:33571911] [10.1016/j.ejmech.2021.113159] |
Source(1):